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Abstract: Collaborative practice among health professionals is slowly coming of age, given
the global focus on efficiency and effectiveness of care to achieve positive patient outcomes
and to reduce the economic burden of fragmented care. Collaborative pharmacy practice (CPP)
is accordingly evolving within different models including: disease management, medication
therapy management, patient centered medical home, and accountable care organizations.
Pharmacist roles in these models relate to drug therapy management and include therapy
introduction, adjustment, or discontinuation, patient counseling and education, and identification,
resolution, and prevention of problems leading to drug interactions and adverse reactions. Most
forms of CPP occur with physicians in various settings. Collaborative practice agreements exist
in many states in the US and are mentioned in the International Pharmaceutical Federation
policy statement. Impetus for CPP comes from health system and economic concerns, as well
as from a regulatory push. There are positive examples in community, ambulatory care, and
inpatient settings that have well documented protocols, indicators of care, and measurement
and reporting of clinical, economic, and patient reported outcomes; however, implementation
of the practice is still not widespread. Conceptual and implementation challenges include health
professional training, attitudes, confidence and comfort levels, power and communication issues,
logistic barriers of time, workload, proximity, resistance to establish and adopt regulations, and
importantly, payment models. Some of the attitudinal and perceptual challenges can be mitigated
by incorporation of interprofessional concepts and practice in health profession education. Other
challenges need to be addressed across health systems, given the inefficiencies and problems
that arise from lack of communication and coordination of patient care including medication
nonadherence, errors and patient safety, complexity of compounded health problems, and
potential liability. The existing evidence needs to be examined to address some challenges and
improve infrastructure for CPP.
Keywords: collaborative pharmacy practice, collaboration model, interprofessional education,
collaborative patient care, coordination of care, continuity of care
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In his book on sociological change, Malcolm Gladwell defines a tipping point as “the
moment of critical mass, the threshold, the boiling point,” when ideas or messages
spread to reach the point where a movement or change occurs.1 A similar pattern
can be drawn for collaborative patient care in the US. As health care costs increased
exponentially through the turn of the twentieth century, and several factors including
an aging population, chronic conditions, and the cost of delivery of complex care
projected an upward trend in future costs, the system began to review solutions.
Adding to the issue was the burgeoning nonadherence to therapy, error rate in health
Integrated Pharmacy Research and Practice 2013:2 1–16
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care delivery, and related suboptimal health outcomes.2
In March 2001, a report titled “Crossing the quality chasm:
a new health system for the 21st century” by the Institute of
Medicine, which is an entity of multidisciplinary experts,
identified a gap (chasm) in the US health care system that
prevents patients from receiving the care that the system is
capable of providing.3 In describing the multiple levels of
systemic change necessary to achieve an improved quality
of care (safe, effective, patient centered, timely, efficient,
and equitable care) for patients with chronic diseases,
the report presented specific areas for systemic redesign
including information technology, alignment of payment
with quality improvement, and more importantly, training of
health professionals in interdisciplinary and evidence based
practice. This report, which appears to be the tipping point
in the awareness for collaborative patient care, shed light on
the need for communication and collaboration among health
professionals as a means of establishing much needed continuity and coordination of care to achieve positive patient
care outcomes.

Objectives

This review aimed to present an update on collaborative
pharmacy practice (CPP); accordingly, the outline of
the paper includes definition, description and evolution,
theories and models of collaborative practice, best practices,
challenges in its implementation, and future directions in
the area.

Introduction

Collaborative patient care practice is focused on a team
based approach to health care of a patient and their family
to ultimately achieve a higher level of continual care.3 Its
genesis in the US goes back to World War II when different medical professionals worked together as a team to
provide effective treatment to wounded soldiers.4 However,
adoption of the model in concept and implementation has
been delayed due to the absence of pertinent state laws and
regulations, the era of super specialization in each health
profession, resistance by providers who felt threatened, and
the lack of a compensation mechanism from third parties
for such care. Recent impetus for collaborative practice has
been from regulatory and national quality organizations.
As evidence began to highlight the correlation between the
absence of continuous, coordinated, and collaborative care
with negative outcomes, collaborative practice within and
among different health professionals has now become a
national agenda. The newly emerging team based approach
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brings health professionals, like physicians, pharmacists,
and nurses, together by engaging them in the provision of
care. As such, in interdisciplinary collaborative teams, every
health care professional has access to important patient
data (ie, laboratory data, total medication history, physical
assessment data) and is therefore aware of a patient’s complete health care needs and can reasonably expect the other
providers’ actions and procedures within the framework of
collaborative health care.5

Search strategy for review

A structured search was performed focusing on the characteristics of CPP. English language articles were identified
in Pubmed up to October 2012 using the following search
terms: “collaborative pharmacy practice”, “interdisciplinary
pharmacy practice”, “multidisciplinary pharmacy practice”,
“physician pharmacist collaboration” “collaborative drug
therapy management”, “collaborative practice agreement”,
“physician pharmacist agreement”, “physician pharmacist
partnership”, “physician pharmacist model”, “physician
pharmacist outcome”, “pharmacy collaborative care
example”, “collaborative practice reimbursement”, and
“medication therapy management”. The references of identified articles were also reviewed to identify other potentially
relevant publications.
Letters, notes, and conference abstracts were excluded.
In total, 142 full text articles were retrieved for review, and
55 were included for reference in the manuscript preparation.
Additional sources such as books, electronic news, organization policy statements, reports, and websites relevant to the
topic were also included for reference.

Description of CPP

CPP has been variable for several reasons. The often noted
cliché in health care has been the presence of silos in practice.
Pharmacists typically focused on prescription dispensing secondary to physician diagnosis and prescribing. Collaborative
practice between pharmacists and physicians may have been
present episodically or anecdotally, but was not actively pursued until patient safety and outcomes became the focus of
health care. The medication focused nature of the pharmacy
profession has led to definitions and examples of CPP that
are centered on physician–pharmacist collaboration.
Collaborative practice involving pharmacists has been
gradually gaining traction based on evidence and regulatory
forces. The Collaborative Practice Agreement Act (CPAAct) that currently exists in 46 US states gives pharmacists
permission to voluntarily enter into collaborative agreements
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with physicians and other providers to offer a variety of
health care services to patients according to a set protocol.6,7
In most US states that allow collaborative management, no
special requirements beyond licensure are required to enter
into such an arrangement. However, in a few US states,
completion of board certification, an American Society of
Health-System Pharmacists (ASHP) accredited residency,
a certain number of years working as a licensed pharmacist
(Bachelor of Pharmacy or Doctor of Pharmacy), and/or
working in certain settings such as in a clinic or in long-term
care are required.8
Collaborative practice between a pharmacist and a
physician focuses on drug therapy management which
includes medication therapy introduction, adjustment, or
discontinuation, patient counseling/education, and lastly, the
identification, resolution, and prevention of any drug-drug
interactions, as well as the identification of adverse reactions
via symptom analysis by the pharmacist, thus eliminating a
potential diagnostic problem. Most forms of collaborative
practice appear to involve pharmacists working with a single
physician or groups of physicians in a medical office, clinic,
or other ambulatory care type setting.9–12 Similar to the CPAAct, pharmacists in other countries have agreements with
physicians; for example, in Quebec, Canada, pharmacists
are allowed to initiate and modify drug therapy based on a
physician’s prescription and request laboratory analyses as
needed.13

Process models for CPP

This section presents an overview of the different types
of collaborative processes that exist in practice or that are
emerging. Disease states for which collaborative practice
models have been reported include dyslipidemia, hypertension,
metabolic syndrome, and chronic kidney disease.11,13–16
In these reports,11,13–16 the overall model is such that the
patients’ first access to healthcare is through their physician.
The physician, in turn, delegates certain responsibilities to the
pharmacist, depending upon the exact collaborative practice
arrangement which has been made between the physician and
pharmacist, in an effort to attain better clinical outcomes for
their patients. Pharmacist responsibilities within these reports
range from identifying and resolving singular medication
therapy problems and prescribing medication renewals to
tasks such as adding, deleting, or otherwise adjusting the
medication therapy regimens of patients, ordering laboratory tests, and performing limited physical assessments.
Through the incorporation of pharmacists, medication
management is typically better optimized and patient
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care outcomes improved. Typically, since physicians and
pharmacists work in close proximity in these types of settings,
interprofessional communication is improved, thus further
fostering collaboration and improving patient care.17
CPP tends to be a global description encompassing many
forms of collaborative practice. Some of the delivery models
of care that exist or are emerging and that involve pharmacists
include: disease management (DM), medication therapy management (MTM), patient centered medical home (PCMH),
accountable care organizations (ACOs). Each of these models
has some characteristics that set it apart but they all revolve
around the concept of collaborative practice to ensure optimal
outcomes. Delivery of care in each model includes provider–
provider and provider–patient communication, coordination,
and continuity of care. In DM, the focus is on patients with
a specific highly prevalent chronic condition that is highly
associated with multiple and complex morbidities if untreated
or uncontrolled, has multiple modalities of treatment
and care, has potential for self-care, and has a significant
economic burden.18,19 Pharmacists have been shown to
improve management of the condition and resultant clinical
and patient reported outcomes, along with reduced economic
burden when they provide patient education on medications,
continuous monitoring in conjunction with physicians, and
close the loop on communication – front- and back-end.
Further, streamlined protocols of care, specified indicators of
change, and documentation of outcomes have been essential
aspects of successful DM programs.20,21
MTM is another model that was officially established
as a program by the Center for Medicare and Medicaid
Services (CMS) as part of the Medicare Modernization and
Improvement Act (2003) to improve medication adherence
and optimize therapeutic outcomes.22 In particular, MTM
has provided an opportunity for pharmacists to provide more
direct patient care services in a community setting. According to the American Pharmacists Association, MTM services
may include: medication therapy reviews, pharmacotherapy
consults, anticoagulation management, immunizations,
health and wellness programs, and many other clinical
services. Reports of pharmacist involvement in community
pharmacy based collaborative practice via MTM have also
been published.7,23,24
PCMH is an emerging model for organizing and delivering care that has been developed in primary care, particularly
in response to a predicted shortage of primary care physicians.
It encompasses a team approach to care that may involve
various professionals: physicians, advanced practice nurses,
physician assistants, nurses, pharmacists, nutritionists,

submit your manuscript | www.dovepress.com

Dovepress

3

Dovepress

Law et al

social workers, educators, and care coordinators. The model
comprises five functions: comprehensive care, patient
centeredness, coordination of care, accessible services, and
quality and safety. A 2009–2010 report of the American
Association of Colleges of Pharmacy identified 151 unique
models that define/discuss pharmacy’s involvement in
primary care services.25 The majority of these models focused
on chronic disease management (eg, diabetes, hypertension,
dyslipidemia), and some specialized services (eg, hepatitis,
oncology, tuberculosis, anticoagulation). Most models were
situated in ambulatory care settings (n = 81, 54%), while integrated settings (n = 33, 22%), community pharmacy (n = 29,
19%), and other (n = 8, 5%) constituted the rest.25
The most recent development is that of ACOs which is
an organization of health care providers that agrees to be
accountable for the quality, cost, and overall care of Medicare
beneficiaries who are enrolled in a traditional fee-for-service
program who are assigned the ACO.”26 The delivery model
aims at payment for performance or aligning provider reimbursements to improved quality and reductions in cost of
care for patients.
In all these models the essential features are patient
centeredness with foundations of communication, health
information technology, workforce development, and
payment alignment.

Frameworks for CPP

To reach a higher level and more effective collaboration
between practitioners, experience, knowledge, and skills are
needed to function in interprofessional health care teams.
To accomplish this, collaborative care needs to be emphasized through interprofessional education (IPE) in medical
and pharmacy schools. In particular, engaging students into
collaborative care in a clinical environment renders great
results.27
The Interprofessional Education Collaborative Expert
Panel 2011, a collaboration of the American Associations
of Colleges of Nursing, Pharmacy, Osteopathic Medicine,
Medical Colleges, Dental Education, and Schools of Public
Health, identified core competencies for interprofessional
collaborative practice in four domains: values/ethics, roles/
responsibilities, interprofessional communication, and teams
and teamwork.28 Their report also outlined desired principles
of these competencies; overall, this report serves as the foundational framework for IPE.
One of the challenges of IPE has been encouraging medical students to embrace this concept broadly. Surveys show
that pharmacy, nursing, and social work students generally
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demonstrate a more positive attitude toward IPE than medical students.4 One success story is the collaborative venture
between the University of Hawaii at Hilo (UHH) College of
Pharmacy (CoP) and the John A. Burns School of Medicine
Family Medicine Program.29 There, the UHH CoP students
work with their professors to engage into a collaborative
practice with physicians and other medical practitioners. The
students use the Hawai‘i Island Family Health Center to teach
students in various health care disciplines in a collaborative
team environment.
Another example is the Inter-Professional Education
(IPE) program developed and used by the authors’ institution (unpublished data, David Dickter, PhD, 2012). The IPEP
curriculum engages health care profession students into
clinical studies where students from all programs collaborate through interprofessional teams. Students learn about a
variety of issues related to IPE including the formation of an
interprofessional team, and the roles and responsibilities of
individual team members to promote a culture of safety and
to enhance quality of life. The program also allows students
to apply the principles they have learned to enhance their
clinical practice skills. Initial surveys of students and faculty show strong positive attitudes toward interprofessional
collaboration. Other factors that influence establishment of
CPP include communication between all stakeholders, team
collaboration, attitudes toward such collaboration, training,
alignment of payment models, time, and workload.30
Whether pharmacists collaborate with physicians within
the confines of a practice arrangement in a community
pharmacy, a medical office, or in an interprofessional
group practice, the first step is to form a successful working relationship. McDonough and Doucette have proposed
a model for how pharmacists can form such relationships
with physicians.31 Within this model, they propose five
stages of development toward a collaborative working
relationship (CWR) (Figures 1 and 2). As pharmacists and
physicians progress through this model, collaboration is
theorized to increase and a greater commitment to maintain
the relationship is expected to occur, and as each profession
learns to depend on the other for input, the relationship is
further strengthened. The CWR model, and progression
through it, is also influenced by the characteristics of each
individual practitioner (eg, age, educational background), the
practitioners sites (eg, proximity between), and exchanges
between each practitioner. While further research and testing of this specific model is needed, pharmacists should be
encouraged to strengthen their relationships with physicians,
as well as other providers, toward achieving a successful
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Medication
therapy reviews
Pharmacotherapy
consults

Immunizations

Health, wellness,
public health

Disease
management/coach

MTM services

Medication safety
surveillance

Pharmacogenomics
applications
Other clinical
services

Anticoagulation
management

Figure 1 Spectrum of medication therapy management services.
Notes: © Copyright American Pharmacists Association (APhA). Reprinted by permission of APhA.22
Abbreviation: MTM, medication therapy management.

CWR leading to positive patient outcomes. Snyder et al
used this framework to describe the professional exchanges
between pharmacists and physicians engaged in successful
CWRs using the Pharmacist-Physician Collaborative Index
(PPCI) and qualitative information on relationship initiation,
trustworthiness, and role specification.23 On the PPCI, both
physicians and pharmacists scored similarly on trustworthiness (39.8 ± 1.7 versus 39.2 ± 3.1, respectively); however,
physicians scored higher on role specification (29.8 ± 2.9
versus 24.6 ± 6.9) and initiation of the relationship (20.3 ± 1
Stage 4: Commitment to CWR

Stage 3: Professional relationship
expansion

Stage 2: Exploration and trial

Individual characteristics
Content characteristics
Exchange characteristics

Stage 1: Professional recognition

Stage 0: Professional awareness

Figure 2 Stepwise approach toward a collaborative working relationship.
Notes: Reprinted with permission Watkins J, Landgraf A, Barnett C, Michaud L.
Evaluation of pharmacist-provided medication therapy management services in an
oncology ambulatory setting. J Am Pharm Assoc (2003). 2012;52:170–174.32
Abbreviation: CWR, collaborative working relationship.
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versus 16.2 ± 2.9). Qualitatively, it was found that establishing
open communication through face to face interactions was
important for pharmacists.

Payment models

One of the challenges to establishing a CPP is the economic
justification for the practice model. The establishment of
MTM by CMS has provided an avenue for pharmacists to
obtain compensation for patient care services in collaborative
practice models. In 2005, the American Medical Association supported this opportunity by introducing three Current
Procedural Terminology (CPT) codes, specifically for pharmacists to bill for MTM services provided to patients.32 However,
these codes have not been widely adopted because third party
payers do not recognize or compensate pharmacists to bill as
independent providers.33 Further, pharmacists express dissatisfaction with the amount of compensation provided by the
few payers. Therefore, pharmacists have sought other options
for billing for these services which include fee for service,
incident-to billing, facility fee billing, direct contracting with
third party payers, and outcomes based billing.34
Incident-to is a billing model where the claim is submitted
under the physician’s name, with the physician overseeing
the work of the pharmacist. This is one way that pharmacists
bill Medicare for the services they provide, since Medicare
does not allow pharmacists to bill independently under their
own name. In order to bill Medicare using incident-to, certain
criteria must be met. The pharmacist must be an employee
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of the physician or medical group and while the supervising
physician does not have to be in the same room during the
visit, the physician must be somewhere on the premises.
Most insurance companies will reimburse only a minimal
amount for services that are billed using incident-to coding.35
Another method of billing insurance companies indirectly
for services provided by pharmacists is facility fee billing.
A transplant clinic in Spokane, Washington, employed this
method by adding the time spent during the pharmacists’
services to the facility fee to account for a higher level of
facilities used for that patient.35 The article did not specify the
entities who were billed, but it was reported that pharmacists
were responsible for increasing the outpatient reimbursement
by approximately $100 per patient.35
Other practices have successfully contracted directly with
third party payers to be reimbursed for their CPP services.
Most of these contracted services are reimbursed on a fee
for service basis. Towncrest Pharmacy is a community, independent pharmacy that contracted with Iowa State Medicaid
to render pharmaceutical case management services, a program that paid pharmacists after each visit for managing the
beneficiaries’ medications.36 Another example is Kerr Drugs
stores, a regional pharmacy chain in North Carolina, which
contracted with the North Carolina Medicaid Division of
Medical Assistance to provide MTM services to their Medicaid beneficiaries. These pharmacists were reimbursed a
fixed rate for every medication review that was completed.37
Fairview Pharmacy Services established pharmaceutical care
services in both Fairview retail pharmacies and primary care
clinics to provide MTM services to Minnesota Medicaid
beneficiaries.38 However, they also offered these services
to contracted self-funded employers as well as private pay
patients. In this program, the pharmacists were paid for
every patient visit with the amount of reimbursement being
dependent on the complexity of the patient’s case.38 While
these are examples of fee for service payment models, some
practices will contract with payers to get reimbursed on a
capitated rate. This occurs particularly with health maintenance organizations which normally pay for services on a
per member per month (PMPM) rate.
Pay for performance (P4P) is another business model
utilized by health plans to pay provider organizations based on
quality performance measures. In California, reimbursement
through the P4P program is somewhat of a hybrid between a
capitated rate and outcomes based payment. The health plan
provides payment to the provider group on a PMPM rate
according to their performance. Based on certain established
quality measures, if the provider group falls in the 75th per-
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centile or higher amongst all the other medical groups, then
the health plan will reimburse 100% of the PMPM rate. The
health plan reimbursed 50% payment for those groups that
fell between the 50th and 74th percentiles and minimal
to no payment if they were lower than 50th percentile.39
Outcomes Pharmaceutical Health Care is an administrative
services company that pays pharmacists for MTM services
on an outcomes based approach. The company collects fees
from health plans or other benefit providers (self-insured
employers, union health plans, state Medicaid programs, or
Medicare Part D plan sponsors) on a capitated basis and uses
those funds to reimburse pharmacists for providing MTM
services to benefit enrollees. The network of pharmacies that
bill the administrative company for these services include
independent, franchise, chain, health system, and consultant
pharmacy providers. Payments to pharmacies are processed
when claims are submitted by the pharmacists and that are
documented in the administrative company’s Internet-based
documentation system.40
In February 2011, an electronic survey was distributed
amongst pharmacists to determine what techniques were being
employed to bill for outpatient MTM services. Of those reportedly billing for their services, 32 were community pharmacists,
32 were pharmacists billing out of a physician’s office, and 31
were pharmacists within a health system outpatient facility.
Sixty five percent of the community pharmacists used fee for
service, 62% directly contracted with the third party insurance
providers, and 56% used the pharmacist CPT codes. For those
billing out of the physician’s office, 71% used incident-to and
22% used the pharmacist CPT codes. Almost half of those
billing within a health system outpatient facility used facility
fee billing, while 36% used the pharmacist CPT codes, and
29% used incident-to billing.

Best practices in the US
and internationally

There are many practice models demonstrating collaborative practices. To highlight the best practice models, the
literature identified earlier was narrowed down to reflect
practice settings that reported positive clinical, humanistic, or
financial outcomes. Table 1 provides a layout of the outcomes
examined in published studies.
Best practice models are described as either in a community pharmacy setting or in a hospital practice, which
includes primary care clinics, nursing facilities, and
any other nontraditional community pharmacy setting.
The Supplementary material provides a detailed narrative of
selected best practices.
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Setting

Stakeholders

Communication

Outcomes

41

Community
pharmacy

Physician,
pharmacist,
nurse,
dietician

Referring physician approved initial
plan of care. Progress notes and followup information from the physician were
communicated to the physician

Clinical: A1C (9.52% vs 7.32%, P = 0.0005) and blood glucose levels
(260 vs 139, P , 0.001) decreased, BMI (31.08 vs 29.69, P = 0.297)
Behavioral (daily BG monitoring, exercising 30 min 3 times a week, daily foot
exam, annual eye exam)

14

Ambulatory
care pharmacy
(medical group)

Physician
(cardiologist),
pharmacist

Clinical: Difference between groups obtaining BP , 130/80 (49.2% vs 31.0%,
P = 0.0456); changes in systolic, diastolic (−12 vs −22, P = 0.0077), pulse
pressure, number of BP medications used, pulse pressures, number of clinic
appointments

42

Ambulatory
care pharmacy
(primary care
clinic)

Physician,
pharmacist

Collaborative practice agreements.
Physician was consulted if dealing with
non-HTN medications.
Documentation by pharmacists was
retrospectively reviewed by physician
Pharmacist note was documented in
EMR and forwarded to PCP for approval
and cosignature

43

Ambulatory
care pharmacy
(primary care
physician group)

Physician,
pharmacist,
physician assistant,
nurse practitioner,
nurse

Electronic summary of visit and a
comprehensive written consult were
provided to the primary care provider.
Physician approval was required for all
clinical interventions

Economic: Medical care (cardiovascular, noncardiovascular, total, emergency
room, hospital), medication costs (cardiovascular, noncardiovascular,
diabetes, total), combined (cardiovascular, noncardiovascular, total)
Clinical: weight, BMI , 25, SBP , 130, DBP , 80, LDL , 100, HDL . 40,
TG , 150, FPG between 70–99, A1C , 7% at baseline, 6 months
(A1C: −1.1%, P , 0.0001 and FPG: −39 mg/dL, P = 0.003) and 12 months
(A1C: −1.1%, P , 0.0001 and FPG: −35 mg/dL, P = 0.005)

44

Ambulatory
care pharmacy
(primary care clinic)

Physician,
pharmacist

Humanistic: Patients’ perception of care measured by CAHPS 2.0
(none were statistically significant), Health-related QOL measure using the
SF-12 (role physical: 2.1, P = 0.001, social functioning: 1.9, P = 0.014, physical
component: 1.5, P = 0.024)

45

Ambulatory
care pharmacy
(outpatient cardiology
department)

Physician,
pharmacist

Each encounter was documented in
the patient’s EMR.
For any potentially harmful or urgent issue,
the patient’s physician was immediately
consulted
Pharmacists suggested recommendations
to physicians through notes written
on an outpatient hospital chart.
Physicians reviewed the note to make
the final decision

46

Staff model
HMO clinic

Physician,
pharmacist,
psychiatrist

Primary care physicians referred patients
with antidepressant therapy to pharmacy
for follow-up. Progress notes, changes/
modifications in therapy and follow-up
assessment information were communicated
to the physician and Liaison psychiatrist

Economic:
Resource utilization patterns
Clinical:
Medication adherence
Humanistic:
Patient satisfaction

Economic: number of office visits; total (4.9 vs 7.2, P , 0.0001), physician
visits (3.2 vs 4.7, P , 0.0001)
Clinical: Difference in mean systolic (143 vs 137, P = 0.007) and diastolic
(78 vs 75, P = 0.003) BP, proportion of subjects achieving BP , 140/90
(44% vs 62%, P = 0.003), self-management knowledge, medication adherence,
Humanistic: QOL using SF-36 (8.5 vs 8.6, P = 0.75)

Clinical: TTR (47.7% vs 39.5%, P = 0.03), rates of thromboembolic
events (0.9% vs 2.3%, P = 0.279) and major bleedings (3.2% vs 3.3%,
P = 0.951)

(Continued)
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Physician,
pharmacist
50

Community-based
family medicine
clinics
Community-based
primary care center
(Japan)
48,49
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Abbreviations: BMI, body mass index; BP, blood pressure; CAHPS, Consumer Assessment of Health Plans; HDL, high density lipoprotein; LDL, low density lipoprotein; QOL, quality of life; TTR, time in therapeutic range; vs, versus;
A1C, hemoglobin A1C; BG, blood glucose level in mg/dL; EMR, electronic medical records; PCP, primary care physician or provider; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; FPG, fasting plasma
glucose; HMO, health maintenance organization; non-HTN, non-hypertension; CV, cardiovascular.

Clinical: BP control
Antihypertensive medication use
Reduction in CV risk factors through lifestyle modifications

Clinical: Guideline adherence improvement
BP control

Clinical: Assessment of binge eating severity
Assessment of depressive symptoms
Humanistic: Health related quality of life assessment

Patients attended lifestyle management
classes led by different providers. However,
there was no communication between
providers reported in this article
Pharmacists reviewed patient’ s medications
and made face to face therapeutic
recommendations to physicians
Pharmacists initially met with patients
for individual consultations. Therapeutic
treatment plans were conveyed to physicians
who prescribed treatment regimens
in consultation with the pharmacist

Communication

Outpatient
University
based clinic
47

Stakeholders
Setting
Citation

Table 1 (Continued)
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Physician,
pharmacist,
behavioral
psychologist
Physician,
pharmacist

Outcomes
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Challenges and barriers in CPP

Collaborative care is aimed at improving the quality of disease
management and standard of health care. As described
previously in Figure 2, a good working relationship between
pharmacists and other healthcare professionals, especially
physicians, is integral in achieving a good corresponding
collaborative care model.23,51–55 However, some barriers
still exist in establishing, developing, and maintaining
CPP. These barriers stem from the inherent nature and
scope of the pharmacy and medical professions, the working relationship between different health care providers,
organizational and financial support, as well as variability
in laws and regulations governing CPP. Specifically, these
barriers are reported to include boundary or turf concerns,
communication breakdowns, power issues, lack of trust,
and distance between practice sites.56
Traditionally, pharmacists have been typically situated in a physician support role and have not contributed
significantly to making major clinical decisions in patient
care. Some pharmacists may lack the advanced clinical
knowledge and skills in physical examination and patient
assessment for providing a full spectrum of patient centered
care. As a result, this can be challenging for pharmacists to
gain approval from physicians regarding clinical decisions.57
This is also an issue in certain countries where the structure
of health systems do allow pharmacists to perform clinical
services, such as laboratory monitoring or adjustment of the
therapeutic regimen for patients.
In addition, practicing pharmacists, especially entry level,
may lack confidence in assuming more responsibilities in providing a higher level of patient care as required in collaborative
care. Further, although there is interest, health profession education around the globe has not yet placed much stress on IPE
in terms of philosophy, academic, or clinical competence.58
Lack of available collaborative practice sites for experiential
or practical training also limits pharmacist experience and
subsequently their level of confidence and comfort in initiating
or working when faced with such an environment.
Pharmacist workload is another problem recognized
by pharmacists as a barrier to effectively initiating or
implementing collaborative care practice with other health
care providers.13,51 Literature suggests that pharmacist
interventions are viewed as extra workload by pharmacists,
and potentially cause significant disruption to pharmacists’
distributive work schedule and pharmacy service provision.9
In addition, settings such as ambulatory care clinics are short
staffed, making it difficult for pharmacists to expand their
clinical functions in collaborative practice.57
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From a physician perspective, their training since
medical school emphasizes their role as leaders who are
deemed fully capable in making independent, major, and
final patient related decisions in an unidisciplinary health
care model.58 Even though efforts have been made to modify
roles to allow engagement of pharmacists in a physician’s
practice, considerable opposition has been raised from
physicians because such reforms are perceived as threats
to the independence and autonomy of the physician’s practice.10,13,51 A difference in attitude toward collaboration has
been observed among practitioners and students, where
medical students view collaborative practice less favorably
than student pharmacists.59 In fact, the above mentioned phenomena are in accordance with the principle of least interest,
which proposes that those who are traditionally in a more
powerful position are less emotionally invested in expressing
eagerness for collaborative relationships with others whom
they consider to be lower in the power hierarchy.4
Another obstacle in establishing collaborative care
practice is to include pharmacists in the physician’s daily
routine. There is concern whether physicians are able to
find time to work with pharmacists in the context of a busy
practice. Additionally, the lack of physician experience
with clinical pharmacy services and formal collaborative
practice legislation were also considered factors that
negatively impacted the pharmacist–primary care provider
relationship in collaborative care.43 In Quebec, Canada, for
instance, physicians and pharmacists often do not work in
close proximity in primary care settings, and in a majority
of the time, telephone conversations and fax transmissions
are the only means by which they interact for the exchange
of professional opinions and judgments.13 In addition,
studies in both Canada and in the US suggested that some
physicians were not well acquainted with pharmacists’
competence in pharmacotherapeutics and ease of access to
patients.7 With this in mind, physicians may need time to
adjust their views on pharmacists, and be ready and generous to fully utilize the skills and expertise of pharmacists
to improve health outcomes. On the other hand, with the
involvement of pharmacists in collaborative care, some
physicians expressed apprehension whether the reduction
in the number of medical visits may negatively impact their
relationship with patients, and reduce the overall quality
of their follow-up.13
Regulations are present to build better CPP; although,
their establishment also came after a struggle. A study
identified the most common barriers in 20 respondent
states in the US to pass their original collaborative practice
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legislations: resistance by physicians or state medical
associations (41%), difficulties in educating health care
professionals about pharmacists’ abilities (16%), opposition
from pharmaceutical manufacturers (16%), opposition
from state nursing associations (9%), and lack of sufficient
lobbying efforts among members (9%).6
Effective administrative support, adequate human and
financial resources, and continual planned assessment of
performance by stakeholders, are all factors necessary for the
planning, development, implementation, and success of a collaborative care model.60,61 Although collaboration, in general,
has been shown to result in cost savings for the health care
system through reduction in frequency of hospitalization and
more appropriate medication use, in the majority of studies,
however, cost effectiveness of the collaborative care model
in improving patient outcomes compared to traditional care
was not assessed precisely.14,51 Every possible effort should
be made to determine whether incorporating a medical team
with members from different health disciplines is worthwhile
by comparing before and after health care expenditure, and
improvement in patient outcomes, at individual practice
settings. Appropriate and feasible compensation mechanisms
to health care providers, including pharmacists, are also
essential in encouraging collaboration between health care
providers in the organization.13 Finally, despite considerable
progress in passing and implementing laws on pharmacist
collaborative practice, ongoing political uncertainty, which
includes opposition from physicians and nurse practitioners,
can become a deterrent for advancement of collaborative
practice.7,62

Looking toward the future of CPP

With a projected deficiency of physicians estimated to be
between 55,000 and 200,000 by 2020, there is definitely a need
for clinical pharmacists to fill the gap through collaborative
practice.43 To further develop CPP internationally, we need
to focus our efforts on education, legislative and regulatory
changes, and reimbursement mechanisms.
In 2010, the International Pharmaceutical Federation
(FIP) released a policy statement on CPP in which they
recommended that each country prepares their pharmacists
and health care systems for CPP.63 The first step in this
process is through a fundamental change in pharmacy
education to include IPE.58 This process will hopefully
achieve more positive attitudes toward collaborative
practice, a better understanding of each profession’s abilities
and limitations, and increased communication between
disciplines.4,58,59,64 Additionally, an important component of
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pharmacy education needs to include developing the skills
required to document comprehensive medication reviews,
interpret lab results, navigate complex patient situations,
and accept clinical uncertainty. These skills will hopefully
engender self-confidence in the student pharmacist to take on
new responsibilities created by CPP and minimize other traits
which would hinder their future ability to succeed in these
new roles.64 Communication skills will also be a necessary
component of pharmacy education to improve interactions
with patients, providers, and administrators.5
IPE is not limited to the didactic curriculum. One article
suggests that if professional students are not able to apply
the theory of IPE in an actual environment, then the didactic
portion of IPE will be ineffective in the long run.61 Academic
clinical rotation sites need to adopt CPP models and create
those practice environments where student pharmacists can
learn how to function in an advanced practice setting and
model the behavior shown to them from their preceptors.
Education is not limited to student pharmacists, however.
Certification or licensing exams will most likely need to demonstrate and ensure the pharmacists’ competence to perform
in a CPP environment, similar to the Pharmacist Prescriptive
Authority Act in New Mexico and the Clinical Pharmacist
Practitioner Act in North Carolina.57,58,65,66
The 2010 FIP policy statement also adds legislative and
regulatory actions for CPP. It recommends that each country
works with their respective governments and health care payers to consider the benefits of CPP to the health care system
and provide legislative and financial support to further this
practice.63 Each country needs to assess their own pharmacy
practice laws and strategize the best pathway to expand those
laws and regulations to facilitate the development of CPPs
that fits with their country’s particular health care system.63
The US has made some headway in this arena with 46 states
having laws and regulations allowing for collaborative drug
therapy management between pharmacists and physicians,
with New Mexico and North Carolina, as mentioned above,
allowing for prescriptive authority for pharmacists through
statute.65,67 Recently, the US Public Health Service sent a
report to the US Surgeon General detailing how pharmacists
can improve health care outcomes, relieve demand on the
health care system, and reduce costs.68 This report led to the
US Surgeon General supporting the concept of pharmacists
as midlevel providers in the US. These have been large gains,
however, the UK is much further along with all pharmacists
eligible to obtain prescribing privileges through further
training and being recognized as Pharmacist Supplementary
Prescribers.65 Despite these prescribing powers granted by
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the government, only a small percentage of pharmacists
in the UK have gone through the National Health Service
approved training program to acquire these powers. One of
the proposed reasons for this phenomenon is difficulty in
demonstrating a financial benefit to employers.65
As the FIP policy statement noted above, legislative and
regulatory involvement also works hand in hand with compensation for clinical services provided. Both are essential to
make CPP sustainable.13,65,69–71 In the UK they have prescriptive authority granted by legislation but the compensation
is not sufficient incentive. In the US we are still working
toward having the legislative authority to prescribe and be
compensated. In the last few years, three bills have been
introduced in the US Congress to allow payments for clinical
services and they have failed to get out of the committee level.
Thus, a more concerted legislative effort involving pharmacists
engaging their locally elected officials is needed to educate
them about what clinical pharmacists can do in a CPP model
to secure adequate compensation for these services. Recently
the Centers for Disease Control and Prevention in the US
released a document titled, “Partnering with Pharmacists in
the Prevention and Control of Chronic Diseases.”70 In this
summary of the available evidence, it states that collaborative
drug therapy management brings a return on investment on
average of 3:1 to 5:1.70 Also, it states that until government
and other third party payers realize the value of CPP services,
the best partners in the meantime are academic institutions
and self-insured employers (companies that assume the health
risk of their employees and other beneficiaries).70 Thus, we
can continue our CPP models with these partners and further
our research in this area to create a more compelling case for
higher level decision makers.

Summary

The time is ripe for interprofessional collaborative practice to
become a reality that all health professions commit to given
the evidence that such practice has the potential to positively
impact continuity and coordination of care to improve medication adherence, reduce adverse events and errors, ultimately
improve patient health outcomes, and reduce economic
burden. Although regulation and education have bought in to
the concept of collaborative practice, and various examples are
in existence, barriers such as resistance from professionals,
logistic issues, and lack of adequate payment mechanisms
continue to impact the expansion of CPP. A combination of
approaches, from education, regulation, and health systems,
is needed to examine the evidence and the infrastructure to
make collaborative practice a feasible model of care.

Integrated Pharmacy Research and Practice 2013:2

Dovepress

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Gladwell M. The Tipping Point: How Little Things can make a Big
Difference. New York: Little Brown; 2000.
2. Kohn LT, Corrigan JM, Donaldson MS, editors. To Err is Human:
Building a Safer Health System. Washington: National Academy Press;
2000.
3. Committee on Quality of Health Care in America. Crossing the Quality
Chasm: A New Health System for the 21st Century. Washington:
National Academy Press; 2001.
4. Van Winkle L, Fjortoft N, Hojat M. Validation of an instrument to
measure pharmacy and medical students’ attitudes toward physicianpharmacist collaboration. Am J Pharm Educ. 2011;75(9):1–6.
5. Levenson S, Saffel D. The consultant pharmacist and the physician in
the nursing home: roles, relationships, and a recipe for success. J Am
Med Dir Assoc. 2007;8:55–64.
6. Punekar Y, Lin SW, Thomas J III. Progress of pharmacist collaborative
practice: status of state laws and regulations and perceived impact of
collaborative practice. J Am Pharm Assoc (2003). 2003;43:503–510.
7. Alkhateeb F, Unni E, Latif D, Shawaqfeh M, Al-Rousan R. Physician
attitudes toward collaborative agreements with pharmacists and their
expectations of community pharmacists’ responsibilities in West
Virginia. J Am Pharm Assoc (2003). 2009;49:797–800.
8. Ukens C. Most states now allow collaborative practice. [webpage
on the Internet]. Drug Topics. Available from: http://drugtopics.
modernmedicine.com/drugtopics/Community+Pharmacy/Moststates-now-allow-collaborativepractice/ArticleStandard/Article/
detail/359816. Accessed December 6, 2012.
9. McKinnon A, Jorgenson D. Pharmacist and physician collaborative
prescribing: for medical renewals within a primary health centre.
Can Fam Physician. 2009;55:e86–e91.
10. Pottie K, Farrel B, Haydt S, et al. Integrating pharmacists into family
practice teams: physicians’ perspectives on collaborative care. Can Fam
Physician. 2008;54:1714–1717. e5.
11. Hammad EA, Yasein N, Tahaineh L, Albsoul-Younes A. A randomized
controlled trial to assess pharmacist-physician collaborative practice in
the management of metabolic syndrome in a university medical clinic
in Jordan. J Manag Care Pharm. 2011;17:295–303.
12. Mino-Leon D, Reyes-Morales H, Jasso L, Doubova SV. Physicians and
pharmacists: collaboration to improve the quality of prescriptions in
primary care in Mexico. Int J Clin Pharm. 2012;34:475–480.
13. Lalonde L, Hudon E, Goudreau J, et al. Physician-pharmacist
collaborative care in dyslipidemia management: The perception of
clinicians and patients. Res Soc Adm Pharm. 2011;7:233–245.
14. Irons BK, Meyerrose G, Laguardia S, Hazel K, Seifert CF.
A collaborative cardiologist-pharmacist care model to improve
hypertension management in patients with or at high risk for
cardiovascular disease. Pharm Prac. 2012;10:25–32.
15. Carter BL, Clarke W, Ardery G, et al; Collaboration Among Pharmacists
Physicians To Improve Outcomes Now (CAPTION) Trial Investigators.
A cluster-randomized effectiveness trial of a physician-pharmacist
collaborative model to improve blood pressure control. Circ Cardiovasc
Qual Outcomes. 2010;3:418–423.
16. St Peter WL, Farley TM, Carter BL. Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney
disease patients. Curr Opin Nephrol Hypertens. 2011;20: 498–503.
17. Kucukarslan S, Lai S, Dong Y, Al-Bassam N, Kim K. Physician beliefs
and attitudes towards collaboration with community pharmacists.
Res Soc Admin Pharm. 2011;7:224–232.
18. Gurnee MC, DaSilva RV. Constructing Disease Management Programs.
[webpage on the Internet]. Managed Care; 2007. Available from: http://
www.managedcaremag.com/archives/9706/9706.disease_man.shtml.
Accessed January 20, 2013.

Integrated Pharmacy Research and Practice 2013:2

Collaborative pharmacy practice
19. Disease Management Association of America. Definition of Disease
Management. Available from: http://www.dmaa.org/definition.html.
Accessed January 22, 2013.
20. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: Clinical
and economic outcomes of a community-based long-term medication
therapy management program for hypertension and dyslipidemia.
J Am Pharm Assoc (2003). 2008;48:23–31.
21. Garrett DG, Bluml BM. Patient self-management program for diabetes:
first-year clinical, humanistic, and economic outcomes. J Am Pharm
Assoc (2003). 2005;45:130–137.
22. American Pharmacists Association [webpage on the Internet]. What
is Medication Therapy Management? Available from: http://www.
pharmacist.com/mtm. Accessed December 10, 2012.
23. Snyder ME, Zillich AJ, Primack BA, et al. Exploring successful
community pharmacist-physician collaborative working relationships
using mixed methods. Res Soc Adm Pharm. 2010;6:307–323.
24. Bryant LJM, Coster G, Gamble GD, McCormick RN. The General
Practitioner-Pharmacist Collaboration (GPPC) Study: a randomized
controlled trial of clinical medication reviews in community pharmacy.
Int J Pharm Pract. 2011;19:94–105.
25. Haines SL, DeHart RM, Hess KM, et al; Professional Affairs
Committee. Report of the 2009–2010 Professional Affairs Committee:
pharmacist integration in primary care and the role of academic
pharmacy. Am J Pharm Educ. 2010;74:S5.
26. Medicare “Accountable Care Organizations” Shared Savings Program – New Section 1899 of Title XVIII, Preliminary Questions and
Answers”. Centers for Medicare and Medicaid Services. Available
from: http://www.healthcare.gov/news/factsheets/2011/03/accountablecare03312011a.html. Accessed April 20, 2013.
27. Arredondo A, Henderson B, Blackburn W, Klotz R. An Advanced
Pharmacy Practice Rotation in a Medical Group Practice:
A Pharmacy Student’s Perspective. California DO Fall 2012. Available
from: ws.westernu.edu/western-News/docs/CA-DO-1.pdf. Accessed
April 15, 2013.
28. Interprofessional Education Collaborative Expert Panel. (2011). Core
Competencies for Interprofessional Collaborative Practice: Report
of an Expert Panel. Washington, DC: Interprofessional Education
Collaborative. Available from: http://www.aacn.nche.edu/educationresources/ipecreport.pdf. Accessed January 25, 2013.
29. Ma C, Holuby R, Bucci L. Physician and pharmacist collaboration:
the University of Hawaii at Hilo college of pharmacy – JABSOM
experience. Hawaii Med J. 2010;69:42–44.
30. O’Daniel M, Rosenstein AH. Professional Communication and Team
Collaboration. In: Hughes RG, editor. Patient Safety and Quality: An
Evidence-Based Handbook for Nurses. Rockville: Agency for Healthcare
Research and Quality (US); 2008:Chapter 33. Available from: http://
www.ncbi.nlm.nih.gov/books/NBK2637/. Accessed April 15, 2013.
31. McDonough RP, Doucette WR. Developing collaborative working
relationships between pharmacists and physicians. J Am Pharm Assoc.
2001;41(5):682–692.
32. Watkins J, Landgraf A, Barnett C, Michaud L. Evaluation of
pharmacist-provided medication therapy management services in an
oncology ambulatory setting. J Am Pharm Assoc (2003). 2012;52:
170–174.
33. Scott MA, Hitch WJ, Wilson CG, Lugo AM. Billing for pharmacists’
cognitive services in physicians’ offices: Multiple methods of
reimbursement. J Am Pharm Assoc (2003). 2012;52:175–180.
34. Beatty SJ, McCormick KM, Beale DJ, et al. Current trends in
outpatient pharmacy services and billing. J Am Pharm Assoc (2003).
2012;52:154–160.
35. Maldonado AQ, Seiger TC, Urann CL, McCleary JA, Goroski AL.
Ojogho ON. Billing for outpatient transplant pharmacy services. Am J
Health Sys Pharm. 2012;69:144–147.
36. McDonough RP, Harthan AA, McLeese KE, Doucette WR. Retrospective
financial analysis of medication therapy management services from
the pharmacy’s perspective. J Am Pharm Assoc (2003). 2010;50:
62–66.

submit your manuscript | www.dovepress.com

Dovepress

11

Dovepress

Law et al
37. Michaels NM, Jenkins GF, Pruss DL, Heidrick JE, Ferreri SP.
Retrospective analysis of community pharmacists recommendations in
the North Carolina Medicaid medication therapy management program.
J Am Pharm Assoc (2003). 2010;50:347–353.
38. Oliveria DJ, Brummel AR, Miller DB. Medication therapy management:
10 years of experience in a large integrated health care system. J Manag
Care Pharm. 2010;16:185–195.
39. Cutler T, Palmieri J, Khalsa M, Stebbins M. Evaluation of the relationship between a chronic disease care management program and California
pay-for-performance diabetes care cholesterol measures in one medical
group. J Manag Care Pharm. 2007;13:578–588.
40. Barnett M, Frank J, Wehring H, et al. Analysis of pharmacist-provided
medication therapy management (MTM) services in community
pharmacies over 7 years. J Manag Care Pharm. 2009;15:18–31.
41. West D, Blevins MA, Brech D, Stotts F, Gardner S. A multidisciplinary
approach in a community pharmacy can improve outcomes for diabetes
patients. Diabetes Educ. 2003;29:962–968.
42. Hunt JS, Siemenczuk J, Pape G, et al. A randomized controlled trial
of team-based care: impact of physician-pharmacist collaboration on
uncontrolled hypertension. J Gen Intern Med. 2008;23(12): 1966–1972.
43. Monte SV, Slaza EM, Albanese NP, Adelman M, Rao G, Paladino JA.
Clinical and economic impact of a diabetes clinical pharmacy service
program in a university and primary care–based collaboration model.
J Am Pharm Assoc (2003). 2009;49:200–208.
44. Isetts B, Schondelmeyer S, Heaton A, Wadd WB, Hardie NA, Artz MB.
Effects of collaborative drug therapy management on patients’ perceptions of care and health-related quality of life. Res Social Adm Pharm.
2006;2:129–142.
45. Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U.
Anticoagulation control of pharmacist-managed collaborative care
versus usual care in Thailand. Int J Clin Pharm. 2012;34:105–112.
46. Finley P, Rens H, Pont J, et al. Impact of a collaborative pharmacy
practice model on the treatment of depression in primary care. Am J
Health Syst Pharm. 2002;59:1518–1526.
47. Malone M, Alger-Mayer S, Anderson D. The lifestyle challenge
program: a multidisciplinary approach to weight management. Ann
Pharmacother. 2005;39:2015–2020.
48. Carter B, Ardery G, Dawson J, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;
169:1996–2002.
49. Weber C, Ernst M, Sezate G, Zheng S, Carter B. Pharmacist-physician
comanagement of hypertension and reduction in 24-hour ambulatory
blood pressures. Arch Intern Med. 2010;170:1634–1639.
50. Tobari H, Arimoto T, Shimojo N, et al. Physician–pharmacist cooperation
program for blood pressure control in patients with hypertension:
a randomized-controlled trial. Am J Hypertens. 2010;23:1144–1152.
51. Dey RM, de Vries MJW, Bosnic-Anticevich S. Collaboration in chronic
care: unpacking the relationship of pharmacists and general medical
practitioners in primary care. Int J Pharm Pract. 2011;19:21–29.
52. Brock KA, Doucette WR. Collaborative working relationships between
pharmacists and physicians: an exploratory study. J Am Pharm Assoc
(2003). 2004;44:358–365.
53. Mehta BH, Snyder ME, Nikitas A. Developing collaborative
relationships between pharmacists and other health professionals. J Am
Pharm Assoc (2003). 2011;51:332–338.
54. Liu Y, Doucette W, Farris K. Examining the development of
pharmacist-physician collaboration over 3 months. Res Social Adm
Pharm. 2010;6:324–333.

12

submit your manuscript | www.dovepress.com

Dovepress

55. Liu Y, Doucette W. Exploring stages of pharmacist-physician
collaboration using the model of collaborative working relationship.
J Am Pharm Assoc (2003). 2011;51:412–417.
56. Miccolo MA, Spanier AH. Critical care management in the 1990s.
Making collaborative practice work. Crit Care Clin. 1993;9:443–453.
57. Edwards J, Edwards S, Saltman D. The role of the nurse practitioner
and clinical pharmacist in collaborative patient care and drug therapy
management in Canadian cancer centres. Report Card on Cancer in
Canada, 2010–2011. 2010;13:30–33.
58. Ray M. Shared borders: Achieving the goals of interdisciplinary patient
care. Am J Health Syst Pharm. 1998;55:1369–1374.
59. Van Winkle L, Bjork B, Chandar N, et al. Interprofessional workshop to
improve mutual understanding between pharmacy and medical students.
Am J Pharm Educ. 2012;76:150.
60. Warrington L, Ayers P, Baldwin A, et al. Implementation of a pharmacistled, multidisciplinary diabetes management team. Am J Health Syst
Pharm. 2012;69:1240–1245.
61. Drummond N, Abbott K, Williamson T, Somji B. Interprofessional
primary care in academic family medicine clinics. Can Fam Physician.
2012;58:e450–e458.
62. Thompson CA. Collaborative practice comes to New York, expands in
Indiana. AJHP News. July 15, 2011.
63. FIP Statement of Policy on Collaborative Pharmacy Practice FIP,
2010. Available from: http://www.fip.org/statements. [homepage on
the Internet]. Accessed April 15, 2013.
64. Farrell B, Ward N, Dore N, Russel G, Geneau R, Evans S. Working in
interprofessional primary health care teams: what do pharmacists do?
Res Social Adm Pharm. 2012;8:1–14.
65. Murawski M, Villa KR, Dole EJ, et al. Advanced-practice pharmacists:
practice characteristics and reimbursement of pharmacists certified for
collaborative clinical practice in New Mexico and North Carolina. Am J
Health Syst Pharm. 2011;68:2341–2350.
66. Martin-Boone JE, Pruce D, Airaksinen M, et al. FIP reference paper
collaborative practice. 2009:1–76. Available from: http://www.fip.org/
statements. [homepage on the Internet]. Accessed April 15, 2013.
67. Academy of Managed Care Pharmacy. Practice Advisory on
Collaborative Drug Therapy Management. Academy of Managed Care
Pharmacy; 2012. Available from: http://www.amcp.org/WorkArea/
DownloadAsset.aspx?id=14710. Accessed December 11, 2012.
68. Giberson S, Yoder S, Lee MP. Improving Patient and Health System
Outcomes through Advanced Pharmacy Practice. A Report to the US
Surgeon General. Office of the Chief Pharmacist. US Public Health
Service; 2011.
69. Moore A, Patterson C, White J, et al. Interprofessional and integrated
care of the elderly in a family health team. Can Fam Physician.
2012;58:e436–e441.
70. Morrison CM, Glover D, Gilchrist SM, et al. Partnering with
Pharmacists in the Prevention and Control of Chronic Diseases. Atlanta:
Centers for Disease Control and Prevention; 2012. Available from: http://
www.cdc.gov/dhdsp/programs/nhdsp_program/docs/pharmacist_guide.
pdf. Accessed April 15, 2013.
71. Howard M, Trim K, Woodward C, et al. Collaboration between
community pharmacists and family physicians: lessons learned from
the seniors medication assessment research trial. J Am Pharm Assoc
(2003). 2003;43:566–572.

Integrated Pharmacy Research and Practice 2013:2

Dovepress

Supplementary material
Community pharmacy

AllCare Pharmacy in Arkadelphia, Arkansas, developed
a diabetes self-management training program according
to the National Standards for Diabetes Self-Management
Education, which is published by the American Diabetes
Association. The program included a physician, pharmacist,
nurse, and dietician. The pharmacist was a full time employee
of the pharmacy and the physician served as a consultant,
with all the other employees only paid part time. Marketing
the service to physicians and nurses included in-person visits
and telephone calls. The program was designed using the
Medicare model where the initial assessment is done one
on one followed by eight weekly group education sessions,
each lasting about 60 minutes. Patients were able to visit the
pharmacy any time they had questions or concerns since the
pharmacist was accessible in the pharmacy during business
hours. This study offered some evidence that providing
diabetes education in a community pharmacy is effective
at improving intermediate clinical outcomes. There was an
average significant reduction in hemoglobin A1C (A1C) by
2.2 percentage points (P = 0.0005) and a decrease in glucose
levels (from 260 mg/dL to 139 mg/dL, P , 0.001), but body
mass index did not change significantly. There was also an
improvement in self-care behaviors which can lead to a
reduction in the risk of diabetes complications.1

Hospital practice

Hospital practice sites in the US that demonstrate best practice
models include a collaborative practice model at Kaiser Permanente, (Oakland, CA, USA), a primary care facility within
a large nonprofit staff model health maintenance organization
(Kaiser Permanente of Northern California).2 In this practice
site, pharmacists provided medication therapy management
for patients who were taking psychiatric medications such as
antidepressants. A cohort of 13 physicians referred patients
who started on antidepressants to the practice model. Clinical
pharmacy specialists coordinated the follow-up with patients
through office visits and telephone calls. Pharmacists had
limited prescribing privileges to allow for dose adjustments
and to add on ancillary medications as deemed necessary.
Pharmacists, physicians, and psychiatrists met regularly to
discuss patients’ progress. Patients’ adherence to treatment,
satisfaction, and costs to the health maintenance organization
(HMO) were compared to a control group of patients being
treated by other physicians in the practice. This multidisciplinary model was associated with a significant improvement
in medication adherence rates (the medication possession
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ratio was 0.81 for the intervention group versus 0.66 for
the control group) in comparison to patients receiving usual
care. It also reduced visits to the primary care physician
(39% for the control group versus 12% for the intervention
group, P = 0.029).
The Lifestyle Challenge Program at a facility in
New York presented results in 2005 of a multidisciplinary
weight management program incorporating diet, lifestyle,
physical activity, and behavioral modification.3 The goal
of the program was to educate patients using behavioral
modification techniques to improve health and weight
loss. Participants were required to attend 1 hour group
based sessions over a 20 week period. Sessions were led
by a facilitator with expertise on the topic being discussed.
Participants were only educated on weight reducing diets,
but were not required to follow a specific dietary plan.
Facilitators included a physician specializing in nutrition,
a pharmacist, a dietician or exercise physiologist, and a
behavioral psychologist. Ninety participants who had multiple obesity related comorbid diseases entered the program.
The 39 patients who completed the study showed significant
improvement in health related quality of life, binge eating
behavior, and depressive symptoms.

Ambulatory care settings

A prospective, cluster randomized controlled clinical trial at
six community based family medicine residency programs in
Iowa evaluated a physician–pharmacist collaborative model
to improve blood pressure control.4,5 The study enrolled 402
patients with uncontrolled hypertension. Clinical pharmacists
made drug therapy recommendations to physicians during
office visits with the patients. Physicians and pharmacists
worked together to decide how best to implement the proposed interventions. Adherence to national guidelines was
improved in the intervention group compared to the control
group (the difference between baseline and a 6 month followup for the mean adherence score was an 8.1% increase for
the control group and a 55.4% increase for the intervention
group, P = 0.09). The mean blood pressure decreased by
6.8/4.5 mmHg in the control group and 20.7/9.7 mmHg in
the intervention group (P = 0.05 for between group systolic
blood pressure comparison). Blood pressure was controlled
in 29.9% of patients in the control group and in 63.9% of
patients in the intervention group (P = 0.001).
A collaborative physician–pharmacist model to improve
diabetes outcomes was initiated in a multispecialty managed
care physician group practice.6 In this model, 22 physicians held practice agreements with two pharmacy specialists
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allowing the pharmacists to initiate, adjust, or discontinue
medications used for the treatment of diabetes, dyslipidemia,
and hypertension based on an approved protocol. Standing
order protocols were in place to allow laboratory tests to be
ordered and referrals to be made. Clinical outcomes measured
included A1C, lipids, and frequency of adherence to preventative care (annual foot and eye examinations and daily aspirin
therapy). The model showcased that pharmacist-coordinated
diabetes management improved clinical markers; there were
significant improvements in A1C reduction and low density
lipoprotein levels, as well as the frequency of adherence to
preventative care.
In 2007, The Texas Tech University Health Sciences
Center’s University Cardiology Group was composed of
four full time cardiologists, with only one of these physicians participating in a collaborative practice model. This
cardiologist referred his patients with hypertension to the
hypertension service, which was staffed by two clinical
pharmacists, at his discretion. Collaborative practice
agreements were utilized to allow the pharmacists to adjust
the patients’ drug therapies on behalf of the physician and
to schedule follow-up appointments as needed. The pharmacists did not use a specific formulary or algorithm, but made
clinical decisions on a case by case basis. The collaborating
cardiologist would be consulted if recommendations were
made on nonhypertension medications or for issues outside
the pharmacists’ scope of practice. Patients were discharged
back to usual care once the patient’s blood pressure was under
control for at least two follow-up visits and maintained for
several months. The cardiology group conducted a study
comparing the quality of care of a physician–pharmacist
collaborative practice model to usual care with no clinical
pharmacy intervention in patients with hypertension in the
same clinical setting. Significant improvements from baseline in systolic blood pressure, diastolic blood pressure, and
pulse pressure were observed in the pharmacist–physician
care model. When compared to usual care, the physician–
pharmacist model was more likely to get patients to an
aggressive goal blood pressure. While the total duration
of follow-up was shorter in the collaborative practice care
model, the frequency of clinic visits and blood pressure
assessments were higher in this model.7
The Providence Primary Care Research Network in
Oregon is comprised of nine community based primary care
clinics with approximately 80 physicians providing care to
110,000 patients. The collaborative practice model of this
network consisted of five pharmacy practitioners. Each
pharmacist had one or two years of ambulatory care residency
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training and was board certified in pharmacotherapy.
Initial visits with the patients included a description by
the pharmacist of the physician–pharmacist collaborative
model of care. The pharmacists followed Network approved
collaborative hypertension management guidelines to review
and adjust patients’ medication therapies. Each pharmacist
had access to a patient’s medical records as well as access
to the primary care physician to discuss treatment plans or
other medical issues as needed. Notes were documented in the
electronic medical record and forwarded to the appropriate
physician for approval and cosignature. In this study, subjects
cared for in the physician–pharmacist team model were 40%
more likely to achieve their goal blood pressure compared to
those cared for by their physician alone. The collaborative
practice model showed an increase in total office visits, with
a significant decrease in the number of physician visits.
Although this study did not assess patient medication cost
share, the higher generic prescribing rate in the collaborative
arm could be considered a surrogate outcome for cost.
However, there were minimal differences between groups
in hypertension-related knowledge, medication adherence,
quality of life, or patient satisfaction.8
Fairview Health Services of Minnesota-St Paul,
Minneapolis, established a Collaborative Drug Therapy
Management (CDTM) model in six primary clinics called
the Collaborative Practice of Pharmaceutical Care. Since
its inception in 1999, the Fairview CDTM has shown
improvements in patients’ goals of therapy and has accounted
for the identification and resolution of more than 12,000 drug
therapy problems. The pharmacists involved in the program
follow a systematic patient care process that includes assessing all of a patient’s medication therapy needs, designing
a pharmaceutical care plan, and conducting follow-up
evaluations to determine outcomes. Therapeutic goals for
each patient included clinical goals following evidence in
the literature or national treatment guidelines, as well as
practical and measurable patient-specific goals. For any
potentially harmful or urgent issues, the patient’s physician
was immediately contacted. Patient perceptions of care
were slightly higher for those who received CDTM services
compared to those who did not, but this was not statistically
significant. Health related quality of life, assessed using the
short-form-12 instrument, showed significant improvement
in the CDTM intervention.9

Academic partnerships

The MedSense Program was developed by the University
of Buffalo School of Pharmacy and Pharmaceutical
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Sciences in collaboration with a regional primary care
physician group. Patients with type 2 diabetes and seen by
the physician group were identified by either a physician,
physician assistant, nurse practitioner, pharmacist, or nurse
and offered a consultation with the MedSense pharmacist.
The MedSense pharmacist was either a clinical assistant
professor of pharmacy with a residency in ambulatory care
and with board certification as a pharmacotherapy specialist,
or a postgraduate year 1 pharmacy practice resident. Neither
pharmacist had any additional diabetes-specific training.
At the initial visit, pharmacists assessed the medication
therapy and then provided the primary care provider with
a brief electronic summary and a comprehensive written
consult. Since New York state legislation does not allow for
collaborative practice agreements between pharmacists and
physicians for pharmacotherapy management, physician
approval was required for all clinical interventions. Patients
enrolled in the program experienced significant reductions
in A1C (−1.1%, P , 0.00001) and fasting plasma glucose
(−39 mg/dL, P , 0.03) from baseline after 6 months.
However, low density lipoprotein, triglycerides, blood
pressure, weight, and body mass index were reduced but
not statistically significant. Also, there was not much difference in any of the clinical outcomes between 6 months and
12 months. While there were a number of patients whose
metabolic parameters improved, there was no difference for
patients whose metabolic parameters were at goal between
baseline and 6 and 12 months. Out of 184 pharmacologic
recommendations, 45% were accepted, 30% were declined,
and 25% were unable to be determined due to lack of
documentation. Medical costs tended to decrease while
prescription medication costs tended to increase, but these
trends were not statistically significant.10

Examples across the globe

Internationally, the following models demonstrate
best practice as seen in the literature. At the Mahart
Nakornratchasima Hospital’s Department of Outpatient Cardiology and Cardiovascular Thoracic Surgery in Thailand,
a pharmacist-managed warfarin therapy collaborative care
model was established. Two clinical pharmacists were
trained through structured didactic teaching, as well as
with practice sessions with case studies for 2 months under
a senior clinical pharmacist who had experience providing
anticoagulation therapy management for over 7 years. The
clinical pharmacists met one on one with patients receiving warfarin therapy to identify any warfarin-related issues
and then made recommendations to the patient’s physician
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in the outpatient hospital chart. Physicians then made the
final decisions regarding the patient’s therapy after reviewing the notes. The hospital conducted a study comparing
the collaborative care model versus usual care without
intensive pharmacist intervention. Patients spent more time
in therapeutic range under the collaborative care model
than those patients under usual care (47.7% versus 39.5%,
P = 0.003) with no difference in bleeding events between the
two groups. The clinical pharmacists made 284 interventions
over a 9 month period and 228 (80%) of them were accepted
by the physicians.11
A study conducted in Japan highlights a collaborative
practice between physicians and pharmacists in the role
of managing hypertension.12 This 6-month randomized
controlled trial for blood pressure control was conducted
at a community based primary care center. Patients in the
intervention group received 15 minute sessions of individual
counseling monthly for 6 months with a pharmacist. The
pharmacist made lifestyle recommendations at each visit,
and offered the physician therapeutic recommendations on
the patient’s antihypertensive medications. Physicians and
pharmacists discussed treatment plans for the patient either
via phone or face to face. The mean decrease in SBP/DBP
was 2.9/3.3 mmHg in the intervention group over baseline
(P = 0.02 and P , 0.00001 for SBP and DBP, respectively).
A significantly higher percentage of patients in the intervention group were able to reduce the use of antihypertensive
medications (P , 0.0001).

A personal example

Roger Klotz and Micah Hata initiated an Anticoagulation
Clinic in a community pharmacy in 2009. A collaborative
practice protocol was created and a physician agreed to review
the protocol and sign off that it was medically appropriate.
The protocol requires that a referral form be completed
and signed by the referring physician and faxed to the
community pharmacy. The protocol allows the pharmacist
to manage the therapy which includes determining the INR
using a point of care device, making a dosage adjustment
when necessary, and determining the next clinic visit/
appointment. The written progress note including the INR,
dosage adjustment, next visit, and any observations made by
the pharmacist is then faxed to the referring physician. The
clinic has been managing many of the patients for 3.5 years
with no difficulties. Initially, the authors thought that the major
barrier to implement this collaborative would be physicians’
concern about a community pharmacist managing a very
difficult therapy, as well as patient resistance to having a
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pharmacist managing their therapy. These turned out to not
be barriers at all. The major barrier to implementation of a
community pharmacy managed anticoagulation clinic was the
payers. Medicare Intermediate stated that pharmacists are not
approved as a provider under Medicare so this would eliminate
a major patient population. The authors then focused on the
private payers which included Medicare Part C payers. Under
Medicare Part C, providers do not bill Medicare and they must
bill the Part C payer. Nonmedicare patients, of course, have
private payers purchased by themselves or their employer so
that would allow the pharmacist managed anticoagulation
clinic to bill these payers. Therapy management must be
billed to the patient’s Major Medical Plan so all billing
must be done via the Form 1500 form. The major payers
require claims to be submitted electronically. Fortunately,
there are a number of organizations that have systems that
allow practitioners to submit electronic claims. We chose
an appropriate medical claims organization and began using
their Web based system. In order to submit claims you must
provide the diagnosis (International Classification of Disease
[ICD]-9 code) that requires the interventions, the appropriate
current procedural terminology (CPT) code(s), the referring
physicians NPI number, the pharmacist provider’s national
provider identification (NPI) number, and the NPI number
for the organization receiving payments. Our referral form
requires the referring physician to provide the diagnosis
and appropriate ICD-9 code so this assures the payer that
there is a medical need for the intervention. Pharmacists
must provide the appropriate CPT codes for the INR test
and the clinic visit. Initially, the payers were hesitant to pay
pharmacists for managing anticoagulation therapy. The major
payer in California was hesitant, and emailed questions over
approximately 4 months which the anticoagulation clinic
pharmacists responded to. Finally, we were notified that the
payer had put the clinic into their computer as an approved
provider. Claims are paid electronically within 30 to 45 days
of submission. We are now receiving reimbursement from

a number of Californian payers which include payment of
claims for Medicare patients who have a preferred provider
organization under Part C. It does take time and effort to
become a provider that is approved to submit claims and
receive payment.
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